Proteins modified with (amino) monosaccharide-biotin adduct

Abstract

A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination

1 . A protein covalently linked to a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct. 
     
     
         2 . The protein according to  claim 1 , wherein said amino-monosaccharide-biotin adduct is amino-mannose-biotin, optionally 2-amino-mannose-biotin. 
     
     
         3 . The protein according to  claim 1 , which is an antibody. 
     
     
         4 . The protein according to  claim 3 , selected from the group consisting of (i) a humanized or chimeric monoclonal IgG antibody; (ii) a mammalian monoclonal IgG antibody; (iii) a mammalian polyclonal IgG antibody; and (iv) a chicken IgY antibody. 
     
     
         5 . The protein according to  claim 4 , wherein the antibody is selected from the group consisting of an anti-tumor associated antigen antibody, an anti-snake venom antibody, an anti-virus antibody and an anti-bacterium antibody. 
     
     
         6 . The protein according to  claim 5 , wherein said anti-tumor associated antigen antibody is an anti-HER2 receptor antibody, said anti-snake venom antibody is an anti-  C. atrox  venom antibody or an anti-viper venom antibody, and said anti-virus antibody is an anti-influenza virus antibody. 
     
     
         7 . The protein according to  claim 6 , wherein said anti-HER2 receptor antibody is Trastuzumab. 
     
     
         8 . The protein according to  claim 1 , wherein the molar ratio of amino-mannose-biotin adduct to IgG antibody, or monosaccharide-biotin adduct to IgG antibody, is between about 2:1 and about 24:1. 
     
     
         9 . The protein according to  claim 8 , wherein the molar ratio is between about 11:1 to about 12:1. 
     
     
         10 . A pharmaceutical composition comprising a protein according to  claim 1 , and a pharmaceutically acceptable carrier. 
     
     
         11 . The pharmaceutical composition according to  claim 10 , comprising an anti-tumor associated antigen antibody. 
     
     
         12 . (canceled) 
     
     
         13 . The pharmaceutical composition according to  claim 11  comprising an anti-HER2 receptor antibody. 
     
     
         14 . The pharmaceutical composition according to  claim 13 , wherein said anti-HER2 receptor antibody is Trastuzumab. 
     
     
         15 . The pharmaceutical composition according to  claim 10 , comprising an anti-virus antibody or an anti-bacterium antibody. 
     
     
         16 . The pharmaceutical composition according to  claim 15 , wherein the anti-virus antibody is an anti-influenza virus antibody. 
     
     
         17 . The pharmaceutical composition according to  claim 10 , comprising an anti-snake venom antibody. 
     
     
         18 . The pharmaceutical composition according to  claim 17 , wherein said anti-snake venom antibody is an anti-  C. atrox  venom antibody or an anti-viper venom antibody. 
     
     
         19 . A method for treating a cancer selected from the group consisting of breast cancer, chronic lymphocytic leukemia, colon cancer, head and neck cancers, lung cancer, acute myelogenous leukemia and non-Hodgkin's lymphoma, comprising administering to a cancer patient a therapeutically effective amount of a protein according to  claim 1 , wherein said protein is an anti-tumor associated antigen antibody. 
     
     
         20 . The method according to  claim 19 , wherein said cancer is breast cancer and said anti-tumor associated antigen antibody is an anti-HER2 receptor antibody.